Table 1.

Relative expression levels of various downstream targets in Akt-active and Akt-inactivate MCL cases from RPPA assay

Akt target	MCL with p-Akt, mean (σ)*	MCL without p-Akt, mean (σ)*	P†
P-MDM2 (Ser166)	3.31 (0.29)	1.17 (0.17)	< .001
P-Bad (Ser136)	5.0 (0.35)	1.37 (0.37)	< .001
P-FKHRL-1 (Ser253)	4.4 (0.27)	1.90 (0.32)	< .001
P-GSK-3β (Ser9)	4.57 (0.36)	3.28 (0.36)	.042
P-mTOR (Ser2448)	5.03 (0.35)	2.22 (0.56)	.001
P-p70S6K (Thr389)	2.61 (0.38)	1.0 (0.10)	.013
P-S6K (Ser235/236)	4.09 (0.21)	1.88 (0.38)	< .001

The mean expression levels for each target were calculated from 17 typical MCL and 12 blastoid variants

^*Mean expression levels (log2) with standard deviations calculated, as described in “Reverse-phase protein assays”

^†Independent 2-tailed Student t test performed for MCL cases with phosphorylated Akt versus MCL without phosphorylated Akt